Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Fri, Jun 26, 2026

1 updates

6:00 PM

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

viridiantherapeutics.com

Wed, May 27, 2026

1 updates

7:00 AM

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

viridiantherapeutics.com

Wed, May 6, 2026

1 updates

11:13 PM

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

viridiantherapeutics.com

Tue, May 5, 2026

3 updates

4:05 PM

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

viridiantherapeutics.com

7:01 AM

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

viridiantherapeutics.com

7:00 AM

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Trial Results • Phase 3viridiantherapeutics.com